Showing 1 - 20 results of 44 for search '"рандомизированное контролируемое исследование"', query time: 0.66s Refine Results
  1. 1
    Academic Journal

    Contributors: The study was performed without external funding., Исследование выполнено без спонсорской поддержки.

    Source: Russian Journal of Child Neurology; Vol 20, No 2 (2025); 12-22 ; Русский журнал детской неврологии; Vol 20, No 2 (2025); 12-22 ; 2412-9178 ; 2073-8803

    File Description: application/pdf

  2. 2
  3. 3
    Academic Journal

    Contributors: The financing was provided by a grant from the Russian Science Foundation «Conducting Basic Scientific Research and Exploratory Research by Individual Scientific Groups». № 23-25-10070., Финансирование осуществлялось за счет средств гранта Российского научного фонда «Проведение фундаментальных научных исследований и поисковых научных исследований малыми отдельными научными группами». № 23-25-10070.

    Source: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 21, № 6 (2024); 42-50 ; Вестник анестезиологии и реаниматологии; Том 21, № 6 (2024); 42-50 ; 2541-8653 ; 2078-5658

    File Description: application/pdf

    Relation: https://www.vair-journal.com/jour/article/view/1105/761; Ишемический инсульт и транзиторная ишемическая атака у взрослых: клинические рекомендации. M.; 2021. URL: https://cr.minzdrav.gov.ru/schema/171_2 (дата обращения: 26.07.2023).; Авидзба А. Р., Саскин В. А., Киров М. Ю. Гемодинамика и реперфузионная терапия при ишемическом инсульте: друзья или враги? // Анестезиология и реаниматология. – 2024. – Т. 2. – С. 91–96. https://doi.org/10.17116/anaesthesiology202402191.; Adams H. P., Bendixen B. H., Kappelle L. J. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment // Stroke. – 1993 – Vol. 1. – P. 35–41. https://doi.org/10.1161/01.str.24.1.35.; Ahmed N., Wahlgren N., Brainin M. et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) // Stroke. – 2009. – Vol. 7. – P. 2442–2449. https://doi.org/10.1161/STROKEAHA.109.548602.; An S. A., Kim J., Kim S. H. et al. Abdominal wall hemorrhage after intravenous thrombolysis for acute ischemic stroke // BMC Neurol. – 2013. – Vol. 13. – P. 6. https://doi.org/10.1186/1471-2377-13-6.; Anderson C. S., Huang Y., Lindley R. I. et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial // Lancet. – 2019. – Vol. 393. – P. 877–888. https://doi.org/10.1016/S0140-6736(19)30038-8.; Béjot Y., Bailly H., Durier J. et al. Epidemiology of stroke in Europe and trends for the 21st century // Presse Med. – 2016. – Vol. 12, Pt 2. – P. 391–398. https://doi.org/10.1016/j.lpm.2016.10.003.; Berge E., Whiteley W., Audebert H. et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke // European Stroke Journal. – 2021. – Vol. 6, № 1. – P. I–LXII. https://doi.org/10.1177/2396987321989865.; Brott T., Adams H. P., Olinger C. P. et al. Measurements of acute cerebral infarction: a clinical examination scale // Stroke. – 1989. – Vol. 20, № 7. – P. 864–870. https://doi.org/10.1161/01.str.20.7.864.; Burgess L. G., Goyal N., Jones G. M. et al. Evaluation of acute kidney injury and mortality after intensive blood pressure control in patients with intracerebral hemorrhage // J Am Heart Assoc. – 2018. – Vol. 7, № 8. – P. e008439. https://doi.org/10.1161/JAHA.117.008439.; Castro P., Azevedo E., Sorond F. Cerebral autoregulation in stroke // Curr Atheroscler Rep. – 2018. –Vol. 20, № 8. –P. 37. https://doi.org/10.1007/s11883-018-0739-5.; Davis S. M., Donnan G. A., Parsons M. W. et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial // Lancet Neurol. – 2008. – Vol. 7, № 4. – P. 299–309. https://doi.org/10.1016/S1474-4422(08)70044-9.; Delgado-Mederos R., Ribo M., Rovira A. et al. Prognostic significance of blood pressure variability after thrombolysis in acute stroke // Neurology. – 2008. – Vol. 71, № 8. – P. 552–558. https://doi.org/10.1212/01.wnl.0000318294.36223.69.; Dohmen C., Bosche B., Graf R. et al. Identification and clinical impact of impaired cerebrovascular autoregulation in patients with malignant middle cerebral artery infarction // Stroke. – 2007. – Vol. 38, № 1. – P. 56–61. https://doi.org/10.1161/01.STR.0000251642.18522.b6.; Furie K. Epidemiology and primary prevention of stroke // Continuum (Minneap Minn). – 2020. – Vol. 26, № 2. – P. 260–267. https://doi.org/10.1212/CON.0000000000000831.; GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 // Lancet Neurol. – 2019. – Vol. 18, № 5. – P. 439–458. https://doi.org/10.1016/S1474-4422(19)30034-1.; Kellum J. A., Lameire N., KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) // Crit Care. – 2013. – Vol. 17, № 1. – P. 204. https://doi.org/10.1186/cc11454.; Ma H., Campbell B. C. V., Parsons M. W. et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke // N Engl J Med. – 2019. – Vol. 380, № 19. – P. 1795–1803. https://doi.org/10.1056/NEJMoa1813046.; Mistry E. A., Hart K. W., Davis L. T. et al. Blood pressure management after endovascular therapy for acute ischemic stroke: the BEST-II randomized clinical trial // JAMA. – 2023. – Vol. 330, № 9. – P. 821–831. https://doi.org/10.1001/jama.2023.14330.; Nam H. S., Kim Y. D., Heo J. et al. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke: The OPTIMAL-BP randomized clinical trial // JAMA. – 2023. – Vol. 330, № 9. – P. 832–842. https://doi.org/10.1001/jama.2023.14590.; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke // N Engl J Med. – 1995. – Vol. 333, № 24. – P. 1581–1587. https://doi.org/10.1056/NEJM199512143332401.; Powers W. J., Rabinstein A. A., Ackerson T. et al. 2018 Guidelines for the Early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association // Stroke. – 2018. – Vol. 49, № 3. – P. e46–e110. https://doi.org/10.1161/STR.0000000000000158.; Seet R. C. S., Rabinstein A. A. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions // Cerebrovasc Dis. – 2012. – Vol. 34, № 2. – P. 106–114. https://doi.org/10.1159/000339675.; Stead L. G., Gilmore R. M., Vedula K. C. et al. Impact of acute blood pressure variability on ischemic stroke outcome // Neurology. – 2006. – Vol. 66, № 12. – P. 1878–1881. https://doi.org/10.1212/01.wnl.0000219628.78513.b5.; Strbian D., Sairanen T., Meretoja A. et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis // Neurology. – 2011. – Vol. 77, № 4. – P. 341–348. https://doi.org/10.1212/WNL.0b013e3182267b8c.; Thomalla G., Simonsen C. Z., Boutitie F. et al. MRI-Guided thrombolysis for stroke with unknown time of onset // N Engl J Med. – 2018. – Vol. 379, № 7. – P. 611–622. https://doi.org/10.1056/NEJMoa1804355.; Toni D., Lorenzano S., Puca E., Prencipe M. The SITS-MOST registry // Neurol Sci. – 2006. – Vol. 27, Suppl 3. – P. 260–262. https://doi.org/10.1007/s10072-006-0632-9.; von Kummer R., Broderick J., Campbell B. et al. The heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy // Stroke. – 2015. – Vol. 46, № 10. – P. 2981–2986. https://doi.org/10.1161/STROKEAHA.115.010049.; Whiteley W. N., Slot K. B., Fernandes P. et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator // Stroke. – 2012. – Vol. 43, № 11. – P. 2904–2909. https://doi.org/10.1161/STROKEAHA.112.665331.; Yang P., Song L., Zhang Y. et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial // Lancet. – 2022. – Vol. 400, № 10363. – P. 1585–1596. https://doi.org/10.1016/S0140-6736(22)01882-7.

  4. 4
    Academic Journal

    Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 1 (2024); 24-32 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 1 (2024); 24-32 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-1

    File Description: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/2177/1623; https://nnp.ima-press.net/nnp/article/downloadSuppFile/2177/912; Игнатьева ВИ, Вознюк ИА, Шамалов НА и др. Социально-экономическое бремя инсульта в Российской Федерации. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2023;123(8-2):5-15. doi:10.17116/jnevro20231230825; Feske SK. Ischemic Stroke. Am J Med. 2021 Dec;134(12):1457-64. doi:10.1016/j.amjmed.2021.07.027. Epub 2021 Aug 27.; The Stroke Action Plan for Europe (SAP-E) is a pan-European initiative that was outlined by the European Stroke Organisation (ESO) and the Stroke Alliance for Europe (SAFE). Available at: https://esostroke.org/projects/stroke-actionplan/#:~:text=The Stroke Action Pl an for,the continent run until%2 02030 (accessed 19.11.2023).; Паспорт национального проекта «Здравоохранение» (утвержден президиумом Совета при Президенте РФ по стратегическому развитию и национальным проектам, протокол от 24.12.2018 № 16). Доступно по ссылке: http://static.government.ru/media/files/gWYJ4OsAhPOweWaJk1prKDEpregEcduI.pdf (дата обращения 19.11.2023).; Stahmeyer JT, Stubenrauch S, Geyer S, et al. The Frequency and Timing of Recurrent Stroke: An Analysis of Routine Health Insurance Data. Dtsch Arztebl Int. 2019 Oct 18;116(42):711-7. doi:10.3238/arztebl.2019.0711; Барулин АЕ, Курушина ОВ, Черноволенко ЕП. Нейрореабилитация при инсульте. Нервные болезни. 2021;(1):72-6. doi:10.24412/2226-0757-2021-12310; Парфенов ВА. Когнитивные нарушения после инсульта. Неврология, нейропсихиатрия, психосоматика. 2019;11(4):22-7. doi:10.14412/2074-2711-2019-4-22-27; Huang Y, Gu C, Zhang W, et al. Early Cognitive Impairment at Acute Stage After Intracerebral Hemorrhage. Curr Neurovasc Res. 2022;19(5):505-14. doi:10.2174/1567202620666221107102321; Yang YM, Zhao ZM, Wang W, et al. Trends in cognitive function assessed by a battery of neuropsychological tests after mild acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020 Jul;29(7):104887. doi:10.1016/j.jstrokecerebrovasdis.2020.104887. Epub 2020 May 10.; Левин ОС, Боголепова АН. Постинсультные двигательные и когнитивные нарушения: клинические особенности и современные подходы к реабилитации. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(11):99-107. doi:10.17116/jnevro202012011199; Боголепова АН, Левин ОС. Когнитивная реабилитация пациентов с очаговым поражением головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(4):115-22. doi:10.17116/jnevro2020120041115; Damsbo AG, Mortensen JK, Kraglund KL, et al. Prestroke Physical Activity and Poststroke Cognitive Performance. Cerebrovasc Dis. 2020;49(6):632-8. doi:10.1159/000511490. Epub 2020 Nov 11.; Li J, Wang J, Wu B, et al. Association Between Early Cognitive Impairment and Midterm Functional Outcomes Among Chinese Acute Ischemic Stroke Patients: A Longitudinal Study. Front Neurol. 2020 Feb 26;11:20. doi:10.3389/fneur.2020.00020; Lo JW, Crawford JD, Desmond DW, et al; Stroke and Cognition (STROKOG) Collaboration. Long-Term Cognitive Decline After Stroke: An Individual Participant Data Meta-Analysis. Stroke. 2022 Apr;53(4):1318-27. doi:10.1161/STROKEAHA.121.035796. Epub 2021 Nov 15.; Клинические рекомендации Министерства здравоохранения Российской Федерации «Ишемический инсульт и транзиторная ишемическая атака», 2021 г. Доступно по ссылке: https://cr.minzdrav.gov.ru/schema/171_2 (дата обращения 19.11.2023).; Herpich F, Rincon F. Management of Acute Ischemic Stroke. Crit Care Med. 2020 Nov;48(11):1654-63. doi:10.1097/CCM.0000000000004597; Rabinstein AA. Update on Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2020 Apr;26(2):268-86. doi:10.1212/CON.0000000000000840; Инструкция по медицинскому применению препарата Проспекта. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0c47ac45-d055-4879-b8f3-bf6d2400318f (дата обращения 19.11.2023).; Белова АН, Богданов ЭИ, Вознюк ИА и др. Терапия умеренных когнитивных расстройств в раннем восстановительном периоде ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(5):33-9. doi:10.17116/jnevro202112105133; Ткачева ОН, Мхитарян ЭА, Колыхалов ИВ и др. Лечение когнитивных, поведенческих и психических нарушений у пациентов с сосудистой деменцией: результаты многоцентрового рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(7):41-9. doi:10.17116/jnevro202312307141; Остроумова ОД, Эбзеева ЕЮ, Полякова ОА и др. Терапия астении у пациентов после острой новой коронавирусной инфекции (COVID-19): результаты многоцентрового рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Терапия. 2022;8(60):146-57. doi:10.18565/therapy.2022.8.146-157; Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi:10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.; Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 Jul;20(7):864-70. doi:10.1161/01.str.20.7.864; Wilson JT, Hareendran A, Hendry A, et al. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke. 2005 Apr;36(4):777-81. doi:10.1161/01.STR.0000157596.13234.95. Epub 2005 Feb 17.; Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37.; Chung CS, Pollock A, Campbell T, et al. Cognitive rehabilitation for executive dysfunction in adults with stroke or other adult non-progressive acquired brain damage. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD008391. doi:10.1002/14651858.CD008391.pub2; Tahmi M, Kane VA, Pavol MA, Naqvi IA. Neuroimaging biomarkers of cognitive recovery after ischemic stroke. Front Neurol. 2022 Dec 14;13:923942. doi:10.3389/fneur.2022.923942; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364-e467. doi:10.1161/STR.0000000000000375. Erratum in: Stroke. 2021;52:e483-e484.; El Husseini N, Katzan IL, Rost NS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Hypertension; and Council on Lifestyle and Cardiometabolic Health. Cognitive Impairment After Ischemic and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2023 Jun;54(6):e272-e291. doi:10.1161/STR.0000000000000430. Epub 2023 May 1.

  5. 5
  6. 6
    Academic Journal

    Source: Буковинський медичний вісник; Том 24, № 1 (93) (2020); 107-114
    Буковинский медицинский вестник; Том 24, № 1 (93) (2020); 107-114
    Bukovinian Medical Herald; Том 24, № 1 (93) (2020); 107-114

    File Description: application/pdf

  7. 7
  8. 8
    Academic Journal

    Source: Acta Biomedica Scientifica; Том 6, № 4 (2021); 74-86 ; 2587-9596 ; 2541-9420

    File Description: application/pdf

    Relation: https://www.actabiomedica.ru/jour/article/view/2975/2193; Бородулина Е.А., Широбоков Я.Е., Гладунова Е.П., Кудлай Д.А. Диагностика и фармакотерапия вирус-ассоциированных поражений легких. Клиническая фармакология и терапия. 2020; 29(3): 61-66. doi:10.32756/ 0869-5490-2020-3-61-66; Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 39(6): 1011-1019. doi:10.1007/s10096-020-03874-z; Львов Д.К., Колобухина Л.В., Дерябин П.Г. Коронавирусная инфекция. Тяжелый острый респираторный синдром. Инфекционные болезни: Новости. Мнения. Обучение. 2015; 4(13): 35-42.; Principi N, Bosis S, Esposito S. Effects of coronavirus infections in children. Emerg Infect Dis. 2010; 16(2): 183-188. doi:10.3201/eid1602.090469; Gagneur A, Vallet S, Talbot PJ, Legrand-Quillien MC, Picard B, Payan C, et al. Outbreaks of human coronavirus in a paediatric and neonatal intensive care unit. Eur J Pediatr. 2008; 167(12): 1427-1434. doi:10.1007/s00431-008-0687-0; Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, Jafari D, Mirzabeigi P. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol. 2021; 895: 173890. doi:10.1016/j.ejphar.2021.173890; Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5): 766-788. doi:10.1016/j.apsb.2020.02.008; Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of Umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2021; 93(1): 481-490. doi:10.1002/jmv.26256; Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on COVID-19: A randomized controlled trial. BMC Infect Dis. 2020; 20(1): 954. doi:10.1186/s12879-020-05698-w; Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and metaanalysis. Virol J. 2020; 17(1): 141. doi:10.1186/s12985-020-01412-z; Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M, et al. Systematic and statistical review of coronavirus disease 19 treatment trials. SN Compr Clin Med. 2020 Jul 15: 1-12. doi:10.1007/s42399-020-00399-6; Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: An open-label control study. Engineering (Beijing). 2020; 6(10): 1192-1198. doi:10.1016/j.eng.2020.03.007; Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final report. N Engl J Med. 2020; 383(19): 1813-1826. doi:10.1056/NEJMoa2007764; Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of Remdesivir for patients with severe COVID-19. N Engl J Med. 2020; 382(24): 2327-2336. doi:10.1056/NEJMoa2007016; Young B, Tan TT, Leo YS. The place for Remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021; 21(1): 20-21. doi:10.1016/S1473-3099(20)30911-7; Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID nineteen study. Chest. 2021; 159(1). 85. doi:10.1016/j.chest.2020.10.009; Hashim A, Mohammed FM, Anwar MR, Dhurgham FF, Khulood KK, Ahmed SA. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020. doi:10.1101/2020.10.26.20219345; ClinacalTrials.gov. URL: https://clinicaltrials.gov/ct2/results?term=ivermectin&recrs=abcdefghl&cond=covid19 [Date of access: 20.07.2021].; Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol. 2020; 2(7): e393-e400. doi:10.1016/S2665-9913(20)30164-8; Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020; 2(6): e325-e331. doi:10.1016/S2665-9913(20)30127-2; Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, MartinSilva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: Case series. Ann Rheum Dis. 2020; 79(10): 1381-1382. doi:10.1136/annrheumdis-2020-217706; Fact sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Bamlanivimab. 2020; Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2021; 384(3): 229-237. doi:10.1056/NEJMoa2029849; Pang J, Xu F, Aondio G, Li Y, Fumagalli A, Lu M, et al. Efficacy and tolerability of Bevacizumab in patients with severe COVID-19. Nat Commun. 2021; 12(1): 814. doi:10.1038/s41467-021-21085-8.; Bevacizumab in severe or critically severe patients with COVID-19 pneumonia – RCT (BEST-RCT). ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT04305106 [Date of access: 07.03.2021].; Bevacizumab in severe or critical patients with COVID-19 pneumonia (BEST-CP). ClinicalTrials.gov. URL: https://clinicaltrials.gov/ct2/show/NCT04275414 [Date of access: 07.03.2021].; Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020; 27: 100553. doi:10.1016/j.eclinm.2020.100553; Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al.; Sarilumab COVID-19 Global Study Group. Sarilumab in pa tients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021: S2213-2600(21)00099-0. doi:10.1016/S2213-2600(21)00099-0; Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92(7): 814-818. doi:10.1002/jmv.25801; Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: A cautionary case report. Chest. 2020; 158(1): e15-e19. doi:10.1016/j.chest.2020.04.024; Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020; 117(20): 10970-10975. doi:10.1073/pnas.2005615117; Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, et al. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020; 99: 491-495. doi:10.1016/j.ijid.2020.08.024; Антонов В.Н., Игнатов Г.Л., Прибыткова О.В., Слепцова С.С., Стребкова Е.А., Худякова Е.А., и др. Опыт применения олокизумаба у больных COVID 19. Терапевтический архив. 2020; 92(12): 148-154. doi:10.26442/00403660.2020.12.200522; Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020; 384(9): 795-807. doi:10.1056/NEJMoa2031994; Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020; 81(2): 318-356. doi:10.1016/j.jinf.2020.04.017; Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020; 81(4): 647-679. doi:10.1016/j.jinf.2020.06.052; Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021. doi:10.1056/NEJMoa2101643; Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes. 2021; 5(3): 605-613. doi:10.1016/j.mayocpiqo.2021.03.007; Avdeev SN, Trushenko NV, Tsareva NA, Yaroshetskiy AI, Merzhoeva ZM, Nuralieva GS, et al. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study. Cytokine. 2021; 146: 155627. doi:10.1016/j.cyto.2021.155627; Павлов Р.Е., Царенко С.В., Секинаева А.В., Рыбин П.Н., Нагибина М.В., Сошникова Е.В., и др. Опыт применения глюкокортикоидов и нетакимаба при лечении больных с COVID-19 в амбулаторных условиях. Клиническая медицина. 2020; 98(6): 449-455. doi:10.30629/0023-2149-2020-98-6-449-455; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021; 384(8): 693-704. doi:10.1056/NEJMoa2021436; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324(13): 1330-1341. doi:10.1001/jama.2020.17023; Li Q, Li W, Jin Y, Xu W, Huang C, Li L, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: A retrospective cohort study. Infect Dis Ther. 2020; 9(4): 823-836. doi:10.1007/s40121-020-00332-3; Keller MJ, Kitsis EA, Arora S, Chen JT, Agarwal S, Ross MJ, et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J Hosp Med. 2020; 15(8): 489-493. doi:10.12788/jhm.3497; Чугунов А.А., Салухов В.В., Данцева О.В., Харитонов М.А., Рудаков Ю.В., Болехан А.В., и др. Некоторые аспекты применения глюкокортикоидных препаратов в комплексном лечении новой коронавирусной инфекции. Медицинский альянс. 2021; 9(1): 43-51. doi:10.36422/23076348-2021-9-1-43-51; https://www.actabiomedica.ru/jour/article/view/2975

  9. 9
  10. 10
  11. 11
    Academic Journal

    Authors: Nikitina, I. M.

    Source: Actual Problems of Pediatry, Obstetrics and Gynecology; No. 2 (2017) ; Актуальные вопросы педиатрии, акушерства и гинекологии; № 2 (2017) ; Актуальні питання педіатрії, акушерства та гінекології; № 2 (2017) ; 2415-301X ; 2411-4944 ; 10.11603/24116-4944.2017.2

    File Description: application/pdf

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20